ALIGOS THERAPEUTICS INC's ticker is ALGS and the CUSIP is 01626L105. A total of 61 filers reported holding ALIGOS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $859,220 | -23.1% | 1,150,227 | -0.1% | 0.00% | – |
| Q2 2023 | $1,117,568 | +11.4% | 1,150,945 | +0.3% | 0.00% | – |
| Q1 2023 | $1,003,162 | -8.4% | 1,147,783 | -0.2% | 0.00% | – |
| Q4 2022 | $1,094,940 | -13.3% | 1,150,148 | +0.2% | 0.00% | – |
| Q3 2022 | $1,263,000 | -8.3% | 1,148,142 | +0.9% | 0.00% | – |
| Q2 2022 | $1,377,000 | -45.9% | 1,137,771 | -3.9% | 0.00% | – |
| Q1 2022 | $2,546,000 | -81.6% | 1,184,258 | +1.7% | 0.00% | -100.0% |
| Q4 2021 | $13,820,000 | +2547.5% | 1,164,300 | +3351.9% | 0.00% | – |
| Q3 2021 | $522,000 | +53.1% | 33,729 | +101.4% | 0.00% | – |
| Q2 2021 | $341,000 | -23.2% | 16,744 | -14.2% | 0.00% | – |
| Q1 2021 | $444,000 | +87.3% | 19,512 | +126.7% | 0.00% | – |
| Q4 2020 | $237,000 | – | 8,607 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 2,320,381 | $1,733,325 | 0.92% |
| TANG CAPITAL MANAGEMENT LLC | 3,329,048 | $2,486,799 | 0.35% |
| Vivo Capital, LLC | 3,547,030 | $2,649,631 | 0.29% |
| Pivotal bioVenture Partners Investment Advisor LLC | 743,215 | $555,182 | 0.22% |
| Newtyn Management, LLC | 920,000 | $687,240 | 0.17% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 631,887 | $472,020 | 0.14% |
| EcoR1 Capital, LLC | 3,948,360 | $2,949,425 | 0.10% |
| HHLR ADVISORS, LTD. | 2,309,764 | $1,725,394 | 0.04% |
| Baker Brothers Advisors | 2,076,400 | $1,551,071 | 0.01% |
| HARBOURVEST PARTNERS LLC | 18,783 | $14,031 | 0.01% |